Johnson D W, Hoppe R T, Cox R S, Rosenberg S A, Kaplan H S
Cancer. 1983 Jul 1;52(1):8-13. doi: 10.1002/1097-0142(19830701)52:1<8::aid-cncr2820520103>3.0.co;2-z.
The records of 1470 patients treated for Hodgkin's disease between 1960 and 1980 were reviewed, and sites of initial involvement were scored. Forty-four patients had disease limited to the chest after clinical and/or pathologic staging. Eighteen asymptomatic patients underwent a staging laparotomy and no occult subdiaphragmatic disease was identified. All 44 patients were treated with irradiation (XRT) to involved (IF), mantle (M), subtotal lymphoid (STLI), or total lymphoid (TLI) fields. Eighteen patients were also treated with chemotherapy, consisting of nitrogen mustard, vincristine, and procarbazine, with or without prednisone (MOP(P)), or procarbazine, melphalan, and vinblastine (PAVe). With a median follow-up of 7.5 years the survival at five and ten years was 93% and 89%, respectively, and the freedom from relapse (FFR) at five and ten years was 81% and 78%, respectively. Ten patients relapsed, all in supradiaphragmatic sites (including six relapses within lung parenchyma). Eight had initially received XRT alone, and two had received combined modality treatment. The risk of relapse in the 26 patients treated with XRT alone varied inversely with the volume irradiated: IF, 100% (3/3); M, 45% (3/7); STLI, 17% (2/12); TLI, 0% (0/4) relapsed. Seven of the eight relapsing patients treated with XRT alone were salvaged with subsequent XRT and/or chemotherapy whereas both of the combined modality patients who relapsed, died with progressive disease despite all salvage therapy.
回顾了1960年至1980年间接受霍奇金病治疗的1470例患者的记录,并对初始受累部位进行了评分。44例患者经临床和/或病理分期后疾病局限于胸部。18例无症状患者接受了分期剖腹探查术,未发现隐匿性膈下疾病。所有44例患者均接受了针对受累野(IF)、斗篷野(M)、次全淋巴结照射(STLI)或全淋巴结照射(TLI)的放射治疗(XRT)。18例患者还接受了化疗,包括氮芥、长春新碱和丙卡巴肼,加或不加泼尼松(MOP(P)),或丙卡巴肼、美法仑和长春花碱(PAVe)。中位随访7.5年,5年和10年生存率分别为93%和89%,5年和10年无复发生存率分别为81%和78%。10例患者复发,均在上膈部位(包括6例肺实质内复发)。8例最初仅接受了XRT,2例接受了综合治疗。仅接受XRT治疗的26例患者的复发风险与照射体积成反比:IF,100%(3/3);M,45%(3/7);STLI,17%(2/12);TLI,0%(0/4)复发。仅接受XRT治疗的8例复发患者中有7例通过后续XRT和/或化疗得到挽救,而2例复发的综合治疗患者尽管接受了所有挽救治疗,仍死于疾病进展。